Highly sensitive and specific diagnosis of COVID-19 by reverse transcription multiple cross-displacement amplification-labelled nanoparticles biosensor

Shijun Li,Weijia Jiang,Junfei Huang,Ying Liu,Lijuan Ren,Li Zhuang,Qinni Zheng,Ming Wang,Rui Yang,Yi Zeng,Yi Wang
DOI: https://doi.org/10.1183/13993003.02060-2020
IF: 24.3
2020-08-28
European Respiratory Journal
Abstract:Background The ongoing outbreak of the novel human coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (also known as 2019-nCoV) has become a global health concern. Rapid and easy-to-use diagnostic techniques are urgently needed to diagnose SARS-CoV-2 infection. Methods We devised a reverse transcription multiple cross-displacement amplification (RT-MCDA) coupled with a nanoparticle-based biosensor assay (RT-MCDA-BS) for rapid, sensitive and specific diagnosis of coronavirus disease 2019 (COVID-19). Two primer sets were designed to target the open reading frame 1a/b and nucleoprotein gene of SARS-CoV-2. A total of 183 clinical samples, including 65 patients with COVID-19 infection and 118 patients with other pathogen infections were used to testify the assay's feasibility. Diagnosis results were reported visually using the biosensor. Findings The assay designed was performed using a simple instrument which could maintain the reaction in a constant temperature at 64°C for only 35 min. The total COVID-19 RT-MCDA-BS test procedure could be finished within 1 h. The COVID-19 RT-MCDA-BS could detect down to five copies of target sequences. Among 65 clinical samples from the COVID-19 patients, 22 (33.8%) positive results were obtained from faeces, nasal, pharyngeal and anal swabs via COVID-19 RT-MCDA-BS assay, while real-time reverse transcription-PCR assay only detected 20 (30.7%) positive results in these samples. No positive results were obtained from clinical samples with non-COVID-19 infections. Interpretation COVID-19 RT-MCDA-BS was a rapid, reliable, low-cost and easy-to-use assay, which could provide an attractive laboratory tool to diagnose COVID-19 in multiple clinical specimens, especially for field, clinic laboratories and primary care facilities in resource-poor settings.
respiratory system
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the need for rapid and accurate diagnosis of Coronavirus Disease 2019 (COVID - 19) on a global scale. With the rapid spread of SARS - CoV - 2 (the novel coronavirus), there is an urgent need to develop a simple, rapid, reliable and easy - to - use diagnostic technique to detect SARS - CoV - 2 infection. Although the existing polymerase chain reaction (PCR) - based techniques are effective, they require expensive thermal cycling equipment and skilled operators, and have a limited positive detection rate in clinical samples, which restricts their application in resource - poor areas. Therefore, the goal of the paper is to develop a new diagnostic method - COVID - 19 RT - MCDA - BS (Reverse Transcription Multiplex Cross - Displacement Amplification - Nanoparticle Biosensor) to achieve rapid, highly sensitive and specific detection of COVID - 19, especially suitable for on - site, clinical laboratories and primary medical facilities, especially in resource - limited environments. Specifically, this research aims to: 1. **Increase the detection speed**: By using simple instruments (such as a water bath or a heating block) to carry out the reaction at a constant temperature, the entire detection process can be completed within 1 hour. 2. **Increase the detection sensitivity**: This method can detect as low as 5 target sequence copy numbers and is more sensitive than the existing PCR techniques. 3. **Increase the detection specificity**: By simultaneously detecting two genes of SARS - CoV - 2 (open reading frame 1a/b and nucleocapsid protein gene), the possibility of false positives and false negatives is reduced. 4. **Simplify the operation process**: Use nanoparticle biosensors for result visualization, without the need for complex equipment and professionals, and is suitable for use in resource - limited environments. In conclusion, this paper proposes a new type of COVID - 19 diagnostic method, aiming to overcome the limitations of existing techniques and provide a rapid, reliable and cost - effective solution.